Cardiólogo y maestro en ciencias.
Instituto Nacional de Cardiología.
Cédula 12343720.
1.
Gómez-Huelgas R, et al. Glucagon-like peptide-1 receptor agonists and sodium−glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. Eur J Intern Med. 2022 Feb 1;96:26–33.
2.
Nauck MA, Quast DR. Cardiovascular Safety and Benets of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne). 2021 Mar 29;12:645566.
3.
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844.